$CNSY

CERENOME, INC. (CNSY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment Capital will support continued CNSide ® commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash r

Cerenome, Inc. (Nasdaq: CNSY) secured a $20M financing facility with 3i, LP, with royalty-based repayments. The funds will support the commercial scale-up of its CNSide cerebrospinal fluid assay platform. Initial funding was provided at closing, with future tranches tied to milestones. The company forecasts a cash runway into 2028.

CERENOME, INC. (PSTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerenome Reports Second Quarter 2026 Financial Results and Business Update HOUSTON, August 14, 2026 – Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted th

Plus Therapeutics, Inc. (Nasdaq: PSTV) said its corporate rebrand to Cerenome will be completed on Aug. 3, 2026. The company will begin trading on Nasdaq under ticker CNSY. Cerenome plans an integrated CNS oncology approach combining its CNSide CSF diagnostics, investigational radiotherapeutic REYOBIQ, and proprietary data and AI platform.

Plus Therapeutics (Nasdaq: PSTV) said updated NCCN CNS cancer guidelines continue to support CSF analysis for leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients on intrathecal therapy. The company links the update to its CNSide CSF assay, citing FORESEE data of more than double tumor-detection sensitivity vs cytology and reporting 126M covered lives and 1,250 tests targeted for 2026.

PLUS THERAPEUTICS, INC. (PSTV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001095981 0001095981 2026-06-01 2026-06-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2

Plus Therapeutics (NASDAQ:PSTV) said its CNSide Diagnostics unit received College of American Pathologists (CAP) accreditation for its CNSide CSF assay platform. The Houston lab passed an on-site CAP inspection covering protocols, documentation, quality control, staff, equipment, and management. The company said accreditation may support payer coverage, reimbursement talks, and faster commercial expansion; shares rose 8.7% to $5.89.

Despite a 4.80% decline in its stock price, Plus Therapeutics (PSTV) announced a significant milestone: its CNSide diagnostic system has secured a dedicated AMA billing code (0640U), effective July 1, 2026. This proprietary code will streamline reimbursement processes for the cerebrospinal fluid tumor cell diagnostic, enhancing its commercial infrastructure and market penetration in CNS oncology. The CNSide platform helps identify malignant cells in CSF, addressing a critical need in treating metastatic central nervous system malignancies.

Plus Therapeutics, Inc. announced the granting of inducement awards to two new employees. These awards, consisting of stock options and restricted stock units, were issued under the Company's 2015 New Employee Incentive Plan and approved by the Compensation Committee as required by Nasdaq Rule 5635(c)(4) to entice new talent. The awards vest over several years, contingent on continued employment.

Plus Therapeutics, Inc. (NASDAQ:PSTV) has appointed Ron Andrews to its Board of Directors, bringing over 35 years of experience in the diagnostics industry. Andrews has a strong background in capital raising and exits, having served in leadership roles at Abbott Diagnostics, Roche Molecular Diagnostics, and LifeTechnologies/Thermo Fisher. This appointment comes as the company faces financial challenges, with its stock having declined significantly over the past year, though InvestingPro analysis suggests it is slightly undervalued.